Clinical Challenges: Myeloma and Concomitant Type 2 Diabetes

Overview

Journal Int J Hematol Oncol Stem Cell Res

Specialty Hematology

Date 2014 Feb 8

PMID 24505516

Citations 3

Authors

Yasar Albushra Abdul Rahiem Ahmed

Awad Eltayeb

Affiliations

Soon will be listed here.

Abstract

Multiple myeloma is a malignant plasma cell disorder that accounts for approximately 10% of all hematologic cancers. It is characterized by accumulation of clonal plasma cells, predominantly in the bone marrow. The prevalence of type 2 diabetes is increasing; therefore, it is expected that there will be an increase in the diagnosis of multiple myeloma with concomitant diabetes mellitus. The treatment of multiple myeloma and diabetes mellitus is multifaceted. The coexistence of the two conditions in a patient forms a major challenge for physicians.

Citing Articles

Smoldering multiple myeloma revealed by superior ophthalmic vein thrombosis.

Bouattour N, Farhat N, Hamza N, Hadjkacem H, Hdiji O, Sakka S Saudi J Ophthalmol. 2021; 34(1):62-65.

PMID: 33542992 PMC: 7849855. DOI: 10.4103/1319-4534.301163.

Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction.

Fraz M, Warraich F, Warraich S, Tariq M, Warraich Z, Khan A Crit Rev Oncol Hematol. 2019; 137:18-26.

PMID: 31014512 PMC: 6508081. DOI: 10.1016/j.critrevonc.2019.02.011.

Myeloma and diabetes mellitus.

Yasri S, Wiwanitkit V South Asian J Cancer. 2014; 3(2):141.

PMID: 24818112 PMC: 4014647. DOI: 10.4103/2278-330X.130469.

References

Badros A, Goloubeva O, Dalal J, Can I, Thompson J, Rapoport A . Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer. 2007; 110(5):1042-9. DOI: 10.1002/cncr.22921. View

Versari D, Herrmann J, Gossl M, Mannheim D, Sattler K, Meyer F . Dysregulation of the ubiquitin-proteasome system in human carotid atherosclerosis. Arterioscler Thromb Vasc Biol. 2006; 26(9):2132-9. DOI: 10.1161/01.ATV.0000232501.08576.73. View

Hu X, Du C, Yang L, Yao X, Hu S . Proteasome inhibitor MG132 suppresses number and function of endothelial progenitor cells: involvement of nitric oxide synthase inhibition. Int J Mol Med. 2010; 25(3):385-92. DOI: 10.3892/ijmm_00000356. View

Argyriou A, Iconomou G, Kalofonos H . Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood. 2008; 112(5):1593-9. DOI: 10.1182/blood-2008-04-149385. View

Jagannath S . Treatment of patients with myeloma with comorbid conditions: considerations for the clinician. Clin Lymphoma Myeloma. 2008; 8 Suppl 4:S149-56. DOI: 10.3816/CLM.2008.s.011. View

Sarwar N, Gao P, Kondapally Seshasai S, Gobin R, Kaptoge S, Di Angelantonio E . Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010; 375(9733):2215-22. PMC: 2904878. DOI: 10.1016/S0140-6736(10)60484-9. View

Knudsen L, Hippe E, Hjorth M, Holmberg E, Westin J . Renal function in newly diagnosed multiple myeloma--a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol. 1994; 53(4):207-12. DOI: 10.1111/j.1600-0609.1994.tb00190.x. View

Gaede P, Lund-Andersen H, Parving H, Pedersen O . Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008; 358(6):580-91. DOI: 10.1056/NEJMoa0706245. View

Meiners S, Laule M, Rother W, Guenther C, Prauka I, Muschick P . Ubiquitin-proteasome pathway as a new target for the prevention of restenosis. Circulation. 2002; 105(4):483-9. DOI: 10.1161/hc0402.102951. View

10.

Kavurma M, Bhindi R, Lowe H, Chesterman C, Khachigian L . Vessel wall apoptosis and atherosclerotic plaque instability. J Thromb Haemost. 2005; 3(3):465-72. DOI: 10.1111/j.1538-7836.2005.01120.x. View

11.

Santostefano M, Zanchelli F, Zaccaria A, Poletti G, Fusaroli M . The ultrastructural basis of renal pathology in monoclonal gammopathies. J Nephrol. 2005; 18(6):659-75. View

12.

Facon T, Mary J, Pegourie B, Attal M, Renaud M, Sadoun A . Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood. 2005; 107(4):1292-8. DOI: 10.1182/blood-2005-04-1588. View

13.

Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D . Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood. 2005; 106(1):35-9. DOI: 10.1182/blood-2005-02-0522. View

14.

Sedaghat D, Zakir R, Choe J, Klapholz M, Saric M . Cardiac amyloidosis in a patient with multiple myeloma: a case report and review of literature. J Clin Ultrasound. 2009; 37(3):179-84. DOI: 10.1002/jcu.20552. View

15.

Pal P . Clinical and electrophysiological studies in vincristine induced neuropathy. Electromyogr Clin Neurophysiol. 1999; 39(6):323-30. View

16.

Bloomgarden Z . American Diabetes Association 60th Scientific Sessions, 2000: glucose tolerance, diabetes and cancer, glycemic control, monitoring, and related topics. Diabetes Care. 2001; 24(4):779-84. DOI: 10.2337/diacare.24.4.779. View

17.

Richardson L, Pollack L . Therapy insight: Influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol. 2005; 2(1):48-53. DOI: 10.1038/ncponc0062. View

18.

Pathak R, Jayaraj K, Blonde L . Thalidomide-associated hyperglycemia and diabetes: case report and review of literature. Diabetes Care. 2003; 26(4):1322-3. DOI: 10.2337/diacare.26.4.1322-a. View

19.

Blade J, Fernandez-Llama P, Bosch F, Montoliu J, Lens X, Montoto S . Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998; 158(17):1889-93. DOI: 10.1001/archinte.158.17.1889. View

20.

Perez-Diaz H, Serrano-Pozo A, Gonzalez-Marcos J . [Multiple myeloma as a treatable cause of stroke: clinical case and review of the literature]. Neurologia. 2007; 22(1):54-7. View